Upcoming Events
 
 6/24/13
  
 
Recent Events
 
2/14/13
 
10/18/12
Peer-to-Peer
 
8/30/12
 
7/26/12

6/29/12
 
6/15/12
 
5/21/12
Cynosure Summit

 
 

ICU Morbidity Clinical Impact Interest Group

Funded by the Gordon and Betty Moore Foundation, the ICU Morbidity Clinical Impact Interest Group (CIIG) addresses two significant, preventable, interconnected causes of morbidity and mortality in ICUs today: delirium and muscle weakness.

Context

ICU FocusDelirium (the acute, fluctuating change in consciousness and cognition that develops over a brief time period) is a frequent complication of critical care and develops in greater than two thirds of critically ill patients.  Without active monitoring, delirium goes undiagnosed in up to 72% of cases. 

Neuromuscular dysfunction occurs in 46% of critically ill patients.  Sedation, delirium, and immobility in ICU patients lead to increased length of stay, increased morbidity and mortality, higher cost of care, and long-term harm including cognitive and functional deficits.

Expert Faculty

Wes Ely, MD MPH, Vanderbilt University Medical Center

Michele Balas, PhD RN APRN-NP CCRN, University of Nebraska Medical Center

Change Bundle

Because ICU acquired weakness and delirium interact with each other and have similar risk factors, an evidence-based treatment bundle has been developed to address both conditions: the ABCDE bundle.
  • Spontaneous Awakening Trials
  • Spontaneous Breathing Trials
  • Coordination of Awakening and Breathing Trials/Choice of Sedative
  • Daily Delirium screening
  • Exercise/Early Mobility

For more information about the ICU Morbidity Clinical Impact Interest Group, please contact Kathleen Carrothers at kcarrothers@cynosurehealth.org.